From Medscape Oncology

Coverage from the

European CanCer Organisation (ECCO) Congress 2017

January 27 - 31, 2017; Amsterdam, The Netherlands

January 27 - 31, 2017 Amsterdam, The Netherlands

ECCO Breath Test for Early Diagnosis of Upper GI Cancer An exhaled breath test that measures just five chemicals could offer an inexpensive alternative to endoscopy in the diagnosis of esophageal and gastric cancers.
Medscape Medical News, January 31, 2017
ECCO Current Melanoma Epidemic Caused by Old Medical Beliefs The dramatic increase in melanoma deaths can be traced back to a vogue for heliotherapy, which involved exposing children to intense UV light.
Medscape Medical News, January 30, 2017
ECCO Outrageous Price Hikes for Generic Cancer Drugs in UK Some generic cancer drugs have increased in price by 1000%, and paying these inflated prices is wasting money for the National Health Service.
Medscape Medical News, January 30, 2017

Conference News

ECCO Better Survival After Breast Conservation Than Mastectomy
Medscape Medical News, February 1, 2017
ECCO Breath Test for Early Diagnosis of Upper GI Cancer
Medscape Medical News, January 31, 2017
ECCO Rapid Diabetes Deterioration -- Sign of Pancreatic Cancer?
Medscape Medical News, January 31, 2017
ECCO Current Melanoma Epidemic Caused by Old Medical Beliefs
Medscape Medical News, January 30, 2017

ECCO Women With DCIS Live Longer Than General Population
Medscape Medical News, January 30, 2017
ECCO Outrageous Price Hikes for Generic Cancer Drugs in UK
Medscape Medical News, January 30, 2017
ECCO ECCO 2017 -- Only Truly Multidisciplinary Cancer Conference
Medscape Medical News, January 20, 2017

Popular News From Past ECC Meetings

'Distressing' Differences in Survival Across Europe Rates of 5-year cancer survival in Europe may have increased in recent years, but marked regional variations remain, data on more than 10 million patients indicate.
Medscape Medical News, Sep 25, 2015
Cancer Surgery Crisis -- Urgent Action Needed A huge shortfall in cancer surgery has been revealed: across the world, less than 25% of patients have access to safe, affordable care, say experts.
Medscape Medical News, Sep 28, 2015
'Most Impressive' PFS Ever Seen in Midgut NET A radiopharmaceutical has achieved the longest progression-free survival (PFS) ever seen in mid-gut neuroendocrine tumors (NETs).
Medscape Medical News, Sep 28, 2015

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

ECCO on Twitter

#ECCO2017 Tweets

Previous Coverage

ECC 2015